Cargando…

Neoadjuvant radiotherapy plus single-incision thoracoscopic surgery in the treatment of type B3 thymomas

BACKGROUND: Although minimally invasive surgery is the standard treatment for thymomas, minimally invasive thymectomy is difficult for patients with type B3 thymomas, especially for giant or aggressive lesions. These tumors are frequently treated with radical radiation therapy or surgery plus adjuva...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wenshan, Wu, Yimin, Huang, Lijian, Chai, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076567/
https://www.ncbi.nlm.nih.gov/pubmed/37035177
http://dx.doi.org/10.3389/fonc.2023.1094974
_version_ 1785020155531624448
author Li, Wenshan
Wu, Yimin
Huang, Lijian
Chai, Ying
author_facet Li, Wenshan
Wu, Yimin
Huang, Lijian
Chai, Ying
author_sort Li, Wenshan
collection PubMed
description BACKGROUND: Although minimally invasive surgery is the standard treatment for thymomas, minimally invasive thymectomy is difficult for patients with type B3 thymomas, especially for giant or aggressive lesions. These tumors are frequently treated with radical radiation therapy or surgery plus adjuvant radiotherapy. Few studies, however, have tested the efficacy of neoadjuvant radiotherapy prior to thoracoscopic surgery. METHODS: Patients with type B3 thymomas >5 cm or with infiltrates into vital organs on CT-guided puncture biopsy who underwent neoadjuvant radiotherapy followed by single-incision minimally invasive thymectomy from March 2016 to July 2020 were retrospectively evaluated. Reduction ratios, TNM stage changes according to WHO stage criteria, resectability, long-term survival, and the response in terms of RECIST v1.1 criteria achieved by preoperative RT were analyzed. RESULTS: The 11 patients who underwent neoadjuvant radiotherapy plus minimally invasive thymectomy included five men and six women, of mean age 49.5 years. Four patients had myasthenia gravis. Neoadjuvant radiotherapy consisted of 50 Gy in 25 fractions, with all patients showing varying degrees of lesion reduction after radiotherapy. Surgery was performed about 1 month after neoadjuvant radiotherapy, with none of these patients having severe radiation pneumonitis. All patients underwent radical resection of the tumor and adjacent tissue, with none experiencing tumor seeding or rupture during surgery. The median postoperative hospital stay was 3 days (range: 2–6 days) and the frequency of additional regular analgesics (including those for wound pain and neuralgia) was 2.5 times per person. On follow-up, one patient experienced pleural metastasis and one experienced pulmonary metastasis, with the other nine patients showing no evidence of tumor recurrence. CONCLUSION: Neoadjuvant radiotherapy followed by minimally invasive surgery was a safe and efficacious procedure for the treatment of type B3 thymomas, with less postoperative pain and faster recovery. This strategy, of tumor shrinkage prior to surgery, may make possible the easier removal of type B3 thymomas by single-incision thoracoscopy.
format Online
Article
Text
id pubmed-10076567
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100765672023-04-07 Neoadjuvant radiotherapy plus single-incision thoracoscopic surgery in the treatment of type B3 thymomas Li, Wenshan Wu, Yimin Huang, Lijian Chai, Ying Front Oncol Oncology BACKGROUND: Although minimally invasive surgery is the standard treatment for thymomas, minimally invasive thymectomy is difficult for patients with type B3 thymomas, especially for giant or aggressive lesions. These tumors are frequently treated with radical radiation therapy or surgery plus adjuvant radiotherapy. Few studies, however, have tested the efficacy of neoadjuvant radiotherapy prior to thoracoscopic surgery. METHODS: Patients with type B3 thymomas >5 cm or with infiltrates into vital organs on CT-guided puncture biopsy who underwent neoadjuvant radiotherapy followed by single-incision minimally invasive thymectomy from March 2016 to July 2020 were retrospectively evaluated. Reduction ratios, TNM stage changes according to WHO stage criteria, resectability, long-term survival, and the response in terms of RECIST v1.1 criteria achieved by preoperative RT were analyzed. RESULTS: The 11 patients who underwent neoadjuvant radiotherapy plus minimally invasive thymectomy included five men and six women, of mean age 49.5 years. Four patients had myasthenia gravis. Neoadjuvant radiotherapy consisted of 50 Gy in 25 fractions, with all patients showing varying degrees of lesion reduction after radiotherapy. Surgery was performed about 1 month after neoadjuvant radiotherapy, with none of these patients having severe radiation pneumonitis. All patients underwent radical resection of the tumor and adjacent tissue, with none experiencing tumor seeding or rupture during surgery. The median postoperative hospital stay was 3 days (range: 2–6 days) and the frequency of additional regular analgesics (including those for wound pain and neuralgia) was 2.5 times per person. On follow-up, one patient experienced pleural metastasis and one experienced pulmonary metastasis, with the other nine patients showing no evidence of tumor recurrence. CONCLUSION: Neoadjuvant radiotherapy followed by minimally invasive surgery was a safe and efficacious procedure for the treatment of type B3 thymomas, with less postoperative pain and faster recovery. This strategy, of tumor shrinkage prior to surgery, may make possible the easier removal of type B3 thymomas by single-incision thoracoscopy. Frontiers Media S.A. 2023-03-23 /pmc/articles/PMC10076567/ /pubmed/37035177 http://dx.doi.org/10.3389/fonc.2023.1094974 Text en Copyright © 2023 Li, Wu, Huang and Chai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Wenshan
Wu, Yimin
Huang, Lijian
Chai, Ying
Neoadjuvant radiotherapy plus single-incision thoracoscopic surgery in the treatment of type B3 thymomas
title Neoadjuvant radiotherapy plus single-incision thoracoscopic surgery in the treatment of type B3 thymomas
title_full Neoadjuvant radiotherapy plus single-incision thoracoscopic surgery in the treatment of type B3 thymomas
title_fullStr Neoadjuvant radiotherapy plus single-incision thoracoscopic surgery in the treatment of type B3 thymomas
title_full_unstemmed Neoadjuvant radiotherapy plus single-incision thoracoscopic surgery in the treatment of type B3 thymomas
title_short Neoadjuvant radiotherapy plus single-incision thoracoscopic surgery in the treatment of type B3 thymomas
title_sort neoadjuvant radiotherapy plus single-incision thoracoscopic surgery in the treatment of type b3 thymomas
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076567/
https://www.ncbi.nlm.nih.gov/pubmed/37035177
http://dx.doi.org/10.3389/fonc.2023.1094974
work_keys_str_mv AT liwenshan neoadjuvantradiotherapyplussingleincisionthoracoscopicsurgeryinthetreatmentoftypeb3thymomas
AT wuyimin neoadjuvantradiotherapyplussingleincisionthoracoscopicsurgeryinthetreatmentoftypeb3thymomas
AT huanglijian neoadjuvantradiotherapyplussingleincisionthoracoscopicsurgeryinthetreatmentoftypeb3thymomas
AT chaiying neoadjuvantradiotherapyplussingleincisionthoracoscopicsurgeryinthetreatmentoftypeb3thymomas